J Korean Med Assoc.  2007 May;50(5):457-463. 10.5124/jkma.2007.50.5.457.

Current Issues of the Charcot-Marie-Tooth Disease

• Choi BO

• KMID: 1958197
• DOI: http://doi.org/10.5124/jkma.2007.50.5.457

Abstract

Hereditary motor and sensory neuropathy (HMSN), or Charcot-Marie-Tooth (CMT) disease, was described by Charcot and Marie in France and, independently, by Tooth in England in 1886. CMT is the most common form of inherited motor and sensory neuropathy, and is a genetically heterogeneous group of disorders in the peripheral nervous system. Traditionally, CMT has been subclassified into autosomal dominant inherited demyelinating (CMT1) and axonal (CMT2) neuropathies, X-linked neuropathy (CMTX), and autosomal recessive inherited neuropathy (CMT4). There are several related peripheral neuropathies, such as Dejerine-Sottas neuropathy (DSN), congenital hypomyelination neuropathy (CHN), hereditary neuropathy with liability to pressure palsies (HNPP), and giant axonal neuropathy (GAN). A large amount of new information on the genetic causes of CMT has become available, and mutations causing the disease have been associated with more than 20 different genes and 40 chromosomal loci. Advances in our understanding of the molecular basis of CMT have revealed an enormous diversity in genetic mechanisms, despite the clinical entity that is relatively uniform at presentation. Recent studies have shown therapeutic effects of certain chemicals in animal models of CMT1A, which suggests potential therapies for the most common form of CMT, CMT1A. This review focuses on the subgroups of inherited motor and sensory neuropathy on which there has been an explosion of new molecular genetic information over the past decade.

Keyword

Hereditary motor and sensory neuropathy; Charcot-Marie-Tooth disease; Peripheral nervous system; Gene; Mutation

MeSH Terms

Axons
Charcot-Marie-Tooth Disease*
England
Explosions
France
Giant Axonal Neuropathy
Hereditary Sensory and Motor Neuropathy
Models, Animal
Molecular Biology
Paralysis
Peripheral Nervous System
Peripheral Nervous System Diseases
Tooth

Figure

• 

  Figure 1 Portraits of Charcot (A), Marie (B), and Tooth (C). In 1886, Frenchmen Jean Martin Charcot (A; 1825~1893) and Pierre Marie (B; 1853~1940), and Briton Howard Henry Tooth (C; 1856~1925), described hereditary motor and sensory neuropathies for the first time.

• 

  Figure 2 Clinical and pathological phenotypes of Charcot-Marie-Tooth disease. Hand muscle atrophy (A) and leg muscle atrophy with high-arched foot deformity (B). Sural nerve teasing studies showed segmental demyelinations (C and D). Electron micrographs showing classic onion bulbs in an unmyelinated axon (E, ×5000), and in a myelinated axon (F, ×14000).

Reference

1. Dyck PJ, Chance P, Lebo R, Carney JA. Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Hereditary motor and sensory neuropathies. Peripheral neuropathy. 1993. 3rd ed. Philadelphia: WB Saunders;1094–1136.

2. Charcot J, Marie P. Sue une forme particulaire d'atrophie musculaire progressive souvent familial debutant par les pieds et les jamber et atteingnant plus tard les mains. Rev Med. 1886. 6:97–138.

3. Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci. 2003. 4:714–726.

4. Shy ME. Charcot-Marie-Tooth disease: an update. Curr Opin Neurol. 2004. 17:579–585.

5. Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med. 2003. 9:1533–1537.

6. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaqlia-S chlupp A, Pellissier JF, Fontes M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004. 10:396–401.

7. Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum Jn, Menhdell JR. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 2005. 65:681–689.

8. Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Vance JM, Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schroder JM, Vance JM. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004. 36:449–451.

9. Verhoeven K, Claeys KG, Züchner S, Schröder JM, Weis J, Timmerman V, Verhoeven K, Claeys KG, Zuchner S, Schroder JM, Weis J, Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van Hul M, Seeman P, Mazanec R, Saifi GM, Szigeti K, Mancias P, Butler IJ, Kochanski A, Ryniewicz B, De Bleecker J, Van den Bergh P, Verellen C, Van Coster R, Goemans N, Auer-Grumbach M, Robberecht W, Milic Rasic V, Nevo Y, Tournev I, Guergueltcheva V, Roelens F, Vieregge P, Vinci P, Moreno MT, Christen HJ, Shy ME, Lupski JR, Vance JM, De Jonghe P, Timmerman V. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain. 2006. 129:2093–2102.

10. Chung KW, Kim SB, Park KD, Choi KG, Lee JH, Choi BO, Chung KW, Kim SB, Park KD, Choi KG, Lee JH, Eun HW, Suh JS, Hwang JH, Kim WK, Seo BC, Kim SH, Son IH, Kim SM, Sunwoo IN, Choi BO. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain. 2006. 129:2103–2118.